Name | Number of supported studies | Average coverage | |
---|---|---|---|
group 3 innate lymphoid cell | 3 studies | 22% ± 5% |
Insufficient scRNA-seq data for expression of TNFSF11 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
intestine | 66% | 55.88 | 640 / 966 | 80% | 3.94 | 422 / 527 |
pancreas | 56% | 8.67 | 183 / 328 | 88% | 8.09 | 157 / 178 |
liver | 98% | 43.75 | 222 / 226 | 37% | 1.46 | 152 / 406 |
stomach | 31% | 2.69 | 110 / 359 | 82% | 4.06 | 235 / 286 |
lung | 55% | 5.61 | 318 / 578 | 55% | 2.37 | 630 / 1155 |
esophagus | 54% | 5.73 | 780 / 1445 | 52% | 1.69 | 96 / 183 |
bladder | 52% | 9.14 | 11 / 21 | 48% | 2.54 | 241 / 504 |
spleen | 94% | 18.38 | 226 / 241 | 0% | 0 | 0 / 0 |
breast | 40% | 17.96 | 184 / 459 | 50% | 2.72 | 561 / 1118 |
kidney | 72% | 9.06 | 64 / 89 | 15% | 0.45 | 137 / 901 |
skin | 51% | 5.71 | 923 / 1809 | 30% | 1.75 | 140 / 472 |
lymph node | 0% | 0 | 0 / 0 | 79% | 6.26 | 23 / 29 |
thymus | 39% | 7.69 | 257 / 653 | 36% | 1.08 | 218 / 605 |
tonsil | 0% | 0 | 0 / 0 | 56% | 2.36 | 25 / 45 |
peripheral blood | 53% | 267.31 | 493 / 929 | 0% | 0 | 0 / 0 |
uterus | 13% | 0.85 | 22 / 170 | 40% | 1.83 | 184 / 459 |
adipose | 45% | 5.59 | 545 / 1204 | 0% | 0 | 0 / 0 |
prostate | 42% | 4.99 | 103 / 245 | 1% | 0.02 | 5 / 502 |
blood vessel | 38% | 12.05 | 512 / 1335 | 0% | 0 | 0 / 0 |
ovary | 7% | 0.34 | 13 / 180 | 12% | 0.36 | 53 / 430 |
heart | 18% | 1.44 | 158 / 861 | 0% | 0 | 0 / 0 |
adrenal gland | 14% | 0.68 | 35 / 258 | 4% | 0.52 | 10 / 230 |
brain | 12% | 1.69 | 312 / 2642 | 1% | 0.02 | 5 / 705 |
muscle | 12% | 1.09 | 98 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0055074 | Biological process | calcium ion homeostasis |
GO_0019221 | Biological process | cytokine-mediated signaling pathway |
GO_0007254 | Biological process | JNK cascade |
GO_0050870 | Biological process | positive regulation of T cell activation |
GO_0051466 | Biological process | positive regulation of corticotropin-releasing hormone secretion |
GO_0019722 | Biological process | calcium-mediated signaling |
GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
GO_0030316 | Biological process | osteoclast differentiation |
GO_0033598 | Biological process | mammary gland epithelial cell proliferation |
GO_0046330 | Biological process | positive regulation of JNK cascade |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_1990830 | Biological process | cellular response to leukemia inhibitory factor |
GO_0038001 | Biological process | paracrine signaling |
GO_1902533 | Biological process | positive regulation of intracellular signal transduction |
GO_0060749 | Biological process | mammary gland alveolus development |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0043406 | Biological process | positive regulation of MAP kinase activity |
GO_0045672 | Biological process | positive regulation of osteoclast differentiation |
GO_0051092 | Biological process | positive regulation of NF-kappaB transcription factor activity |
GO_0006955 | Biological process | immune response |
GO_0044691 | Biological process | tooth eruption |
GO_0070371 | Biological process | ERK1 and ERK2 cascade |
GO_0043123 | Biological process | positive regulation of canonical NF-kappaB signal transduction |
GO_0002158 | Biological process | osteoclast proliferation |
GO_0045453 | Biological process | bone resorption |
GO_0043491 | Biological process | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0034112 | Biological process | positive regulation of homotypic cell-cell adhesion |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0071812 | Biological process | positive regulation of fever generation by positive regulation of prostaglandin secretion |
GO_0001503 | Biological process | ossification |
GO_0002548 | Biological process | monocyte chemotaxis |
GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
GO_2001206 | Biological process | positive regulation of osteoclast development |
GO_0045780 | Biological process | positive regulation of bone resorption |
GO_0033209 | Biological process | tumor necrosis factor-mediated signaling pathway |
GO_0036035 | Biological process | osteoclast development |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005615 | Cellular component | extracellular space |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0032813 | Molecular function | tumor necrosis factor receptor superfamily binding |
GO_0042802 | Molecular function | identical protein binding |
GO_0005164 | Molecular function | tumor necrosis factor receptor binding |
GO_0005515 | Molecular function | protein binding |
GO_0005125 | Molecular function | cytokine activity |
Gene name | TNFSF11 |
Protein name | Tumor necrosis factor ligand superfamily member 11 (Osteoclast differentiation factor) (ODF) (Osteoprotegerin ligand) (OPGL) (Receptor activator of nuclear factor kappa-B ligand) (RANKL) (TNF-related activation-induced cytokine) (TRANCE) (CD antigen CD254) [Cleaved into: Tumor necrosis factor ligand superfamily member 11, membrane form; Tumor necrosis factor ligand superfamily member 11, soluble form] Receptor activator of nuclear factor kappa B ligand 3 (Tumor necrosis factor (Ligand) superfamily, member 11, isoform CRA_b) Tumor necrosis factor ligand superfamily member |
Synonyms | RANKL OPGL hRANKL hCG_32838 3 TNLG6B TRANCE |
Description | FUNCTION: Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy . Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation (By similarity). . |
Accessions | ENST00000398795.7 [O14788-1] Q54A98 O14788 Q5T9Y4 ENST00000358545.6 [O14788-2] |